AbbVie ABBV

NYS: ABBV | ISIN: US00287Y1091   12/01/2026
220,04 USD (-0,02%)
(-0,02%)   12/01/2026

13 januari 2026 · AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans · Persbericht

12 januari 2026 · AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors · Persbericht

12 januari 2026 · AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States · Persbericht

12 januari 2026 · West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie · Persbericht

7 januari 2026 · AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call · Persbericht

5 januari 2026 · AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

2 december 2025 · AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers · Persbericht

2 december 2025 · À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine · Persbericht

24 november 2025 · AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference · Persbericht

18 november 2025 · AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma · Persbericht

14 november 2025 · AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer · Persbericht

13 november 2025 · AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ · Persbericht

12 november 2025 · Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence · Persbericht

31 oktober 2025 · AbbVie Reports Third-Quarter 2025 Financial Results · Persbericht

29 oktober 2025 · The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year · Persbericht

29 oktober 2025 · AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo · Persbericht

28 oktober 2025 · Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM · Persbericht

21 oktober 2025 · The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients · Persbericht

20 oktober 2025 · RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor · Persbericht

20 oktober 2025 · Europees aandelennieuws · Bolero.be

Novo Nordisk benoemt Greg Miley tot wereldwijd hoofd corporate affairs. De Deense farmaceut heeft de Amerikaanse farmabestuurder Greg Miley aangesteld als wereldwijd hoofd corporate affairs, met als doel de relaties met...

Mijn selecties